Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries
- 382 Downloads
Approved doses of a number of drugs in Japan are known to be different from those in the United States (US) and the European Union (EU), and doses are often set lower for the Japanese than for the western people. Similarly, some oncology drugs also have lower dose approved for the Japanese than for the western people. A total of 40 oncology drugs were approved as new molecular entities in Japan between 2001 and 2013. Of the 40 drugs, 21 were molecularly targeted drugs and 13 were cytotoxic drugs. Five (12.5 %) of the 40 drugs had different approved dose from that in the US and the EU. Of the 13 cytotoxic drugs, four drugs (30.8 %) differed in approved dose, while all the molecularly targeted drugs (21 of 21 drugs) had the same approved dose. We compared the maximum tolerated dose (MTD) of the 21 molecularly targeted drugs in the Japanese with that in the western people and found that the MTD was determined lower in the Japanese than that in the western people (two drugs), was not different (10 drugs), and MTD was not determined in the Japanese and incommensurable because of the different dose range tested in Japan (nine drugs). All the molecularly targeted drugs are the same in approved doses and few molecularly targeted drugs differ in MTD between Japan and the Western countries.
KeywordsAnticancer drug Ethnic difference Approval dose Maximum tolerated dose Oncology Japan
Authors thank to Kentaro Takeda for his statistical advice and Minako Takizawa for her assistance in writing the manuscript.
No specific funding was disclosed.
Conflict of interest disclosures
Hideki Maeda is an employee of Astellas Pharma Inc.
- 10.Usami M, Akaza H, Arai Y, Hirano Y, Kagawa S et al (2007) Bicalutamide 80mg combined with a luteinizing hormone relieasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis 10(2):194–201CrossRefPubMedGoogle Scholar
- 11.Akaza H, Yamaguchi A, Matsuda T, Igawa M et al (2004) Superior anti-tumor efficacy of bicalutamide 80mg in combination with luteinizing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 34(1):20–28CrossRefPubMedGoogle Scholar
- 15.Salzberg M (2012) First-in-human phase 1 studies in oncology: the new challenge for investigative sites. Rambam Maimoinides Med J 3(2):e0007Google Scholar
- 17.Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare., Basic Principles of Global Clinical Trials. Notification no. 0928010, 2007; http://www.pmda.go.jp/operations/notice/2007/file/0928010-e.pdf. Accessed Feb 2014
- 21.Pharmaceuticals and Medical Devices Agency Review report of docetaxel 75 mg/m2 (in Japanese), http://www.info.pmda.go.jp/shinyaku/P201000172/780069000_22100AMX01369_A100_1.pdf. Accessed Feb 2014